electroCore (ECOR) vs Solana (HSDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
electroCore (ECOR) has outperformed Solana (HSDT) over the past year, losing 6.2% versus a loss of 53.7%. Over five years, ECOR leads with a -61.2% price change compared with -100.0% for HSDT. Solana is the larger company by market cap ($93.7 million vs $40.8 million), about 2.3 times the size.
electroCore converts more of its revenue into profit, with a net margin of -43.6% versus -679.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ECOR | HSDT |
|---|---|---|
| Share price | $4.42 | $1.49 |
| Market cap | $40.78M | $93.70M |
| 1-day change | -8.87% | -10.24% |
| YTD return | -1.45% | -48.44% |
| 1-year return | -6.16% | -53.73% |
| 5-year return | -61.23% | -100.00% |
| P/E ratio (TTM) | — | 0.02 |
| EPS (TTM) | $-1.36 | $87.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $32.03M | $6.02M |
| Revenue growth (YoY) | +27.20% | +1057.12% |
| Net income (latest FY) | $-13.97M | $-40.89M |
| Gross margin | 86.75% | 91.69% |
| Operating margin | -41.06% | -4052.52% |
| Net margin | -43.60% | -679.57% |
| 52-week high | $12.70 | $4.36 |
| 52-week low | $3.90 | $1.19 |
| Distance from 52-week high | -65.20% | -65.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +333.71% | +134.90% |
| Average volume | 120.32K | 579.67K |
| Shares outstanding | 9.23M | 62.89M |
| Employees | 83 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Solana is about 2.3 times larger than electroCore by market value ($93.70M vs $40.78M).
- ECOR has outperformed HSDT by 47.6 percentage points over the past year.
- electroCore is more profitable, keeping -43.6 cents of every revenue dollar as net income versus -679.6 cents for Solana.
- Solana grew revenue faster in its latest fiscal year (+1057.12% vs +27.20%).
About electroCore
ECOR stock →electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees
About Solana
HSDT stock →Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 21 employees
ECOR vs HSDT FAQ
Which is bigger, electroCore or Solana?
Solana (HSDT) is larger, with a market capitalization of $93.70M compared with $40.78M for electroCore (ECOR).
Which stock has performed better over the past year, ECOR or HSDT?
ECOR returned -6.16% over the past 12 months, compared with -53.73% for HSDT (price return, excluding dividends). Past performance does not predict future results.
Are electroCore and Solana in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.